{"filing":{"accession_number":"0001104659-26-074577","cik":"0001850119","ticker":"IPSC","company_name":"Century Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-16","report_date":null,"primary_document":"tm2617925d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1850119/000110465926074577/tm2617925d1_8k.htm"},"events":[{"id":11300,"run_id":9918,"accession_number":"0001104659-26-074577","anchor_item_number":"5.02","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.85,"summary":"The disclosure centers on an Amended and Restated Employment Agreement with Chad Cowan, Ph.D., the Chief Scientific Officer, modifying his compensation structure to part-time status with a reduced annual salary of $296,150 and pro-rated performance-based bonus eligibility. While the agreement also addresses termination provisions, the principal disclosed action is a compensatory arrangement modification for a named executive officer, which falls squarely within exec_compensation rather than exec_departure (no departure occurred) or exec_appointment (no new role assumed).","company_name":"Century Therapeutics, Inc.","ticker":"IPSC","filing_date":"2026-06-16","form":"8-K","submitted_at":null,"items":[{"id":7857,"accession_number":"0001104659-26-074577","item_number":"5.02","item_title":"Departure","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The disclosure centers on an Amended and Restated Employment Agreement with Chad Cowan, Ph.D., the Chief Scientific Officer, modifying his compensation structure to part-time status with a reduced annual salary of $296,150 and pro-rated performance-based bonus eligibility. While the agreement also addresses termination provisions, the principal disclosed action is a compensatory arrangement modification for a named executive officer, which falls squarely within exec_compensation rather than exec_departure (no departure occurred) or exec_appointment (no new role assumed).","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-16T20:08:57.501703+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":7857,"accession_number":"0001104659-26-074577","item_number":"5.02","item_title":"Departure","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The disclosure centers on an Amended and Restated Employment Agreement with Chad Cowan, Ph.D., the Chief Scientific Officer, modifying his compensation structure to part-time status with a reduced annual salary of $296,150 and pro-rated performance-based bonus eligibility. While the agreement also addresses termination provisions, the principal disclosed action is a compensatory arrangement modification for a named executive officer, which falls squarely within exec_compensation rather than exec_departure (no departure occurred) or exec_appointment (no new role assumed).","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-16T20:08:57.501703+00:00","company_name":"Century Therapeutics, Inc.","ticker":"IPSC","filing_date":"2026-06-16"}]}